Posted by Michael Wonder on 06 Jul 2026
PHARMAC funds another ADHD medicine to improve supply
24 June 2026 - PHARMAC will fund another brand of methylphenidate to help improve supply and provide more treatment options for people with attention deficit hyperactivity disorder (ADHD).
The Rubifen LA (long-acting) brand of methylphenidate will be funded for people with ADHD. It is a generic version of the already funded Ritalin LA brand and will be available in the same strengths (10 mg, 20 mg, 30 mg and 40 mg), along with an additional 60 mg strength.
